Leerink Partners Maintains Market Perform on 10x Genomics, Raises Price Target to $90
Benzinga Newsdesk 1 month ago
Analyst RatingsNewsPrice Target
Leerink Partners analyst Mike Kratky maintains 10x Genomics (NASDAQ:TXG) with a Market Perform and raises the price target from $40 to $90.
Leerink Partners analyst Mike Kratky maintains 10x Genomics (NASDAQ:TXG) with a Market Perform and raises the price target from $40 to $90.